New pharmacological approach to heart failure treatment

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorPham, Hung Trung
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentSzentmiklósi, József
dc.contributor.opponentHalasi , Barbara Dóra
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.date.accessioned2025-04-15T14:00:21Z
dc.date.available2025-04-15T14:00:21Z
dc.date.created2025-03-07
dc.description.abstractHeart failure has long been among the most fatal diseases worldwide. That calls for research and development of new approaches to heart failure. With two treatment principles: either to increase myocardial contraction in case of acute/advanced heart failure or to decrease workload for the heart in case of chronic heart failure, new drug candidates are expected to increase patient’s survival and quality of life. Medications are valuable if they are used to manage underlying risk factors or systemic/cardiovascular diseases as well. Among the newly investigated approaches, sodium-glucose cotransporter 2 inhibitors, angiotensin receptor/neprilysin inhibitor, and soluble guanylate cyclase stimulators/activators are the most successful ones. They have proved their superiority repeatedly in clinical trials of HFrEF treatment, and are all being investigated for HFpEF. Targeting cardiac myofilaments, myosin modulators aims to change the heart contractility without affecting intracellular calcium level. Besides that, cardiac metabolism pathway and the hallmark of metabolism shifting in heart failure open up a new promising direction. Inflammatory background also plays an important role in pathogenesis, so various anti-inflammatory approaches have been tried for management of heart failure.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.coursespecOrvosbiológia-farmakológia
dc.description.degreeegységes, osztatlan
dc.format.extent32
dc.identifier.urihttps://hdl.handle.net/2437/389196
dc.language.isoen
dc.rights.infoHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectheart failure
dc.subjectpharmacological treatment
dc.subjectnew approach
dc.subject.dspaceMedicine::Pharmacology
dc.titleNew pharmacological approach to heart failure treatment
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
Thesis - Pham Hung Trung - electronic submission.pdf
Méret:
2.17 MB
Formátum:
Adobe Portable Document Format
Leírás:
Thesis - Pham Hung Trung - electronic submission.pdf
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás: